MedPath

The therapeutic effect of the combination of altplas and ibtifibatide (integrilin) in comparison with altplas (r-TPA) alone, in the treatment of acute ischemic stroke

Phase 2
Conditions
Acute Ischemic Stroke.
Cerebellar stroke syndrome
G46.4
Registration Number
IRCT20170117032025N9
Lead Sponsor
Hamedan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
50
Inclusion Criteria

Patients should have a serious measurable neurological defect on the NIHSS stroke scale due to focal ischemia of the brain (NIHSS score> 5).
Intravenous therapy should be started within 3 hours of the onset of stroke symptoms.

Exclusion Criteria

Suspect subarachnoid hemorrhage, even if the brain CT scan is normal

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Cerebral hemorrhage. Timepoint: Admission, discharge and three months later. Method of measurement: By NIHSS(National Institutes of Health Stroke Scale) criteria.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath